Breaking News

Harbour BioMed Launches Élancé Therapeutics

Élancé Therapeutics will use HCAb-based bispecific antibody technology to improve current obesity treatment.

By: Rachel Klemovitch

Assistant Editor

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics in immunology and oncology, launched Élancé Therapeutics (Élancé). Using Harbour BioMed’s HCAb-based bispecific antibody technology, Élancé aims to develop innovative therapies addressing key challenges in current obesity treatment, including muscle preservation and long-term efficacy. Élancé is building bispecific antibody programs to improve ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters